TGAN vs. AIP, VLN, SKYT, NVEC, CAN, AAOI, MX, QUIK, AXTI, and ATOM
Should you be buying Transphorm stock or one of its competitors? The main competitors of Transphorm include Arteris (AIP), Valens Semiconductor (VLN), SkyWater Technology (SKYT), NVE (NVEC), Canaan (CAN), Applied Optoelectronics (AAOI), Magnachip Semiconductor (MX), QuickLogic (QUIK), AXT (AXTI), and Atomera (ATOM). These companies are all part of the "semiconductors & related devices" industry.
Transphorm (NASDAQ:TGAN) and Arteris (NASDAQ:AIP) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Transphorm has higher earnings, but lower revenue than Arteris. Arteris is trading at a lower price-to-earnings ratio than Transphorm, indicating that it is currently the more affordable of the two stocks.
Transphorm has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Arteris has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
In the previous week, Arteris had 5 more articles in the media than Transphorm. MarketBeat recorded 6 mentions for Arteris and 1 mentions for Transphorm. Arteris' average media sentiment score of 0.52 beat Transphorm's score of 0.00 indicating that Arteris is being referred to more favorably in the news media.
66.5% of Transphorm shares are owned by institutional investors. Comparatively, 64.4% of Arteris shares are owned by institutional investors. 2.5% of Transphorm shares are owned by insiders. Comparatively, 33.7% of Arteris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Transphorm currently has a consensus target price of $5.75, suggesting a potential upside of 17.11%. Arteris has a consensus target price of $13.40, suggesting a potential upside of 58.96%. Given Arteris' stronger consensus rating and higher probable upside, analysts plainly believe Arteris is more favorable than Transphorm.
Arteris has a net margin of -69.70% compared to Transphorm's net margin of -177.91%. Transphorm's return on equity of -149.03% beat Arteris' return on equity.
Arteris received 13 more outperform votes than Transphorm when rated by MarketBeat users. Likewise, 57.69% of users gave Arteris an outperform vote while only 50.00% of users gave Transphorm an outperform vote.
Summary
Arteris beats Transphorm on 12 of the 18 factors compared between the two stocks.
Get Transphorm News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Transphorm Competitors List
Related Companies and Tools
